...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Arthritis and Rheumatism >Patient: and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes
【24h】

Patient: and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes

机译：患者：与类风湿性关节炎的Golimalab对类毒素治疗的医生期望：期望与临床和生活质量之间的关系

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. Rheumatoid arthritis (RA) management involves improving clinical outcomes and quality of life (QOL). Golimumab is used as add-on therapy for patients who have failed disease-modifying antirheumatic drugs (DMARDs). This GO-MORE subanalysis investigated relationships between patient and physician expectations and outcomes. Methods. GO-MORE was an open-label, multinational, prospective study in biologic agent-naive patients with active RA despite DMARD treatment. Patients received 50 mg subcutaneous golimumab monthly for 6 months. At baseline and month 3, patients rated treatment expectations for the following 3 months using 5-point scales (where 1 = good and 5 = poor). Outcomes were compared among expectation tertiles: most positive, intermediate, and least positive. At baseline and month 3, physicians predicted patient disease state 3 months later.Results. At baseline, 3,280 efficacy-evaluable patients with moderate (21,3%) or high (78.7%) disease activity had mean ?SD disease duration of 7.6 ?7.9 years, mean ?SD Health Assessment Questionnaire (HAQ) disability index (DI) score of 1.44 ?0.67, and mean ?SD EuroQol 5-domain (EQ-5D) score of 0.42 ?0.33. Patients reported high treatment expectations (mean 1.43); 95.9% expected golimumab to be better than current treatment. Patients with fewer DMARD failures, higher disease activity, shorter disease duration, younger age, and female sex reported higher expectations (P < 0.05 for all). After 6 months, patients with the most positive expectations had higher remission rates (P < 0.0001) and greater HAQ DI (P < 0.0001) and EQ-5D (P < 0.0001) score improvements. At baseline, physicians expected 29.6% and 59.2% of patients to attain remission and low disease activity, respectively, after 3 months.Conclusion. Patients had high expectations for golimumab treatment. Patients with more positive expectations had greater remission rates, improvements in function, and QOL.
机译：客观的。类风湿性关节炎（RA）管理涉及提高临床结果和生活质量（QOL）。 Golimumab被用作患有失败的疾病修饰的抗抗性药物（DMARDS）的患者的加入治疗。这种远离的细分分析调查了患者和医生期望和结果之间的关系。方法。尽管DMARD治疗，但GO-More是一种开放标签，跨国，在生物药剂 - 天真患者中患有活性RA的患者。患者每月接受50毫克皮下的Golimumab 6个月。在基线和第3个月，患者使用5分尺度（其中1 =良好，5 =差）进行以下3个月的治疗期望。结果在期望结节中比较了结果：最积极，中间，最不积极的。在基线和第3个月，医生预测患者疾病状态3个月后。结果。在基线，3,280名疗效评价患者中度（21,3％）或高（78.7％）疾病活动有意思？SD疾病持续时间为7.6？7.9岁，意味着？SD健康评估问卷（HAQ）残疾指数（DI）得分为1.44？0.67，平均值？SD Euroqol 5-域（EQ-5D）得分为0.42？0.33。患者报告了高治疗期望（平均1.43）; 95.9％预期的Golimumab比目前的治疗更好。 DMARD失败的患者较少，疾病活动较高，疾病持续时间较短，年龄较小，女性性别均报告了更高的期望（全部P <0.05）。 6个月后，最阳性预期的患者具有更高的缓解率（P <0.0001）和更高的HAQ DI（P <0.0001）和EQ-5D（P <0.0001）得分改进。在基线，医生预计患者的29.6％和59.2％分别在3个月后分别获得缓解和低疾病活动。结论。患者对Golimalab治疗具有很高的期望。患者更积极的期望具有更大的缓解率，功能改善，QOL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号